Alpha Tau MedicalDRTS +4.67%32 5-Year RORE % is -3.94 as of Mar. 2026. GuruFocus rates DRTS with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,133 Biotechnology companies, Alpha Tau Medical ranks better than 60.37% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Alpha Tau Medical's 5-Year RORE % for the quarter that ended in Mar. 2026 was -3.94%.
The industry rank for Alpha Tau Medical's 5-Year RORE % or its related term are showing as below:
DRTS's 5-Year RORE % is ranked better than 60.37% of 1133
companies
in the Biotechnology industry
Industry Median: -10.57
vs DRTS: -3.94
Alpha Tau Medical (NAS:DRTS) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Alpha Tau Medical 5-Year RORE % Related Terms
Alpha Tau Medical 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRTS vs ORIC, OLMA, KURA: 5-Year RORE % Comparison
For the Biotechnology subindustry, Alpha Tau Medical's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical 5-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Alpha Tau Medical (DRTS) has a 5-Year RORE % of -3.94 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #449 out of 1133 companies in the Biotechnology industry, placing it in the top 39.6%.
Is Alpha Tau Medical's 5-Year RORE % too high?
Alpha Tau Medical's current 5-Year RORE % is -3.94. Based on the distribution chart, Alpha Tau Medical ranks #449 out of 1133 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alpha Tau Medical has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's 5-Year RORE % compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #449 out of 1133 companies for 5-Year RORE %. This puts Alpha Tau Medical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Alpha Tau Medical and its competitors. Alpha Tau Medical's current 5-Year RORE % is -3.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current 5-Year RORE % of -3.94. The current 5-Year RORE % is -3.94. Alpha Tau Medical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current 5-Year RORE % is -3.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
32GF Score
Get the complete analysis for DRTS
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
